GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » E10

Biomarin Pharmaceutical (BSP:B1MR34) E10 : R$-2.64 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was R$1.145. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is R$-2.64 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 6.50% per year. During the past 5 years, the average E10 Growth Rate was 6.00% per year. During the past 10 years, the average E10 Growth Rate was -14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Biomarin Pharmaceutical was 20.60% per year. The lowest was -63.90% per year. And the median was 6.00% per year.

As of today (2024-06-08), Biomarin Pharmaceutical's current stock price is R$210.00. Biomarin Pharmaceutical's E10 for the quarter that ended in Mar. 2024 was R$-2.64. Biomarin Pharmaceutical's Shiller PE Ratio of today is .


Biomarin Pharmaceutical E10 Historical Data

The historical data trend for Biomarin Pharmaceutical's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical E10 Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -3.51 -4.16 -3.48 -2.73

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.26 -2.99 -3.04 -2.73 -2.64

Competitive Comparison of Biomarin Pharmaceutical's E10

For the Biotechnology subindustry, Biomarin Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Shiller PE Ratio falls into.



Biomarin Pharmaceutical E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomarin Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.145/131.7762*131.7762
=1.145

Current CPI (Mar. 2024) = 131.7762.

Biomarin Pharmaceutical Quarterly Data

per share eps CPI Adj_EPS
201406 -0.257 100.560 -0.337
201409 0.058 100.428 0.076
201412 -0.621 99.070 -0.826
201503 -0.675 99.621 -0.893
201506 -0.793 100.684 -1.038
201509 -1.171 100.392 -1.537
201512 0.757 99.792 1.000
201603 -0.943 100.470 -1.237
201606 -4.416 101.688 -5.723
201609 -0.358 101.861 -0.463
201612 -0.889 101.863 -1.150
201703 -0.141 102.862 -0.181
201706 -0.346 103.349 -0.441
201709 -0.110 104.136 -0.139
201712 -0.494 104.011 -0.626
201803 -0.426 105.290 -0.533
201806 -0.170 106.317 -0.211
201809 -14.380 106.507 -17.792
201812 -0.058 105.998 -0.072
201903 -0.615 107.251 -0.756
201906 -0.405 108.070 -0.494
201909 0.618 108.329 0.752
201912 0.164 108.420 0.199
202003 1.075 108.902 1.301
202006 -0.415 108.767 -0.503
202009 10.827 109.815 12.992
202012 0.309 109.897 0.371
202103 0.254 111.754 0.300
202106 0.176 114.631 0.202
202109 -0.528 115.734 -0.601
202112 -0.905 117.630 -1.014
202203 1.568 121.301 1.703
202206 0.379 125.017 0.399
202209 -0.105 125.227 -0.110
202212 -0.004 125.222 -0.004
202303 0.703 127.348 0.727
202306 0.704 128.729 0.721
202309 0.519 129.860 0.527
202312 0.269 129.419 0.274
202403 1.145 131.776 1.145

Add all the adjusted EPS together and divide 10 will get our e10.


Biomarin Pharmaceutical  (BSP:B1MR34) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Biomarin Pharmaceutical E10 Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines